Timing of antiretroviral therapy initiation after diagnosis of recent human immunodeficiency virus infection and CD4+ T-cell recovery. (March 2016)

• Record Type: Journal Article
• Authors: Ding, Y.; Duan, S.; Wu, Z.; Ye, R.; Yang, Y.; Yao, S.; Wang, J.; Xiang, L.; Jiang, Y.; Lu, L.; Jia, M.; Detels, R.; He, N.
• Is Part Of: Clinical microbiology and infection. Volume 22:Number 3(2016)
• Page Start: 290.e5
• Page End: 290.e8
• Publication Date: 2016-03
• Subjects: Antiretroviral therapy -- CD4+T cells -- China -- human immunodeficiency virus -- immune recovery -- recent infection; Medical microbiology -- Periodicals; Diagnostic microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.01
• DOI: 10.1016/j.cmi.2015.11.007
• Languages: English
• ISSNs: 1198-743X

Abstract

Abstract: We retrospectively examined the timing of antiretroviral therapy (ART) initiation and CD4 + T-cell recovery over 36 months among recent human immunodeficiency virus (HIV) infections using BED (HIV-1 subtypes B, E and D) immunoglobulin G capture enzyme immunoassay (BED-CEIA). Regardless of baseline CD4 + counts, individuals ( n = 393) who initiated ART >2 months after diagnosis had significantly decreased probability and rate of achieving CD4 + counts ≥900 cells/μL or ≥600 cells/μL than those individuals ( n = 135) who started ART earlier (≤2 months). But the mean CD4 + counts in two groups converged after 30 months of treatment. Early ART initiation leads to accelerated CD4 + recovery, but does not offer a long-term advantage in CD4 + counts.